An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy is a phase 2, interventional study registered as NCT07631871 by Haihua Yuan, with a registry enrolment figure of 10 participants, started 2026-06-15 and due to reach its primary completion in 2029-12-31. Interventions recorded: Zanidatamab. Conditions listed: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor; Endometrial Neoplasm; Urothelial Carcinoma (UC); Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Cervical Neoplasms; Ovarian Neoplasms. Primary outcome: Objective Response Rate, ORR. Pancreatic eligibility wording from the registry: "Qualified tumor types include but are not limited to endometrial carcinoma, urothelial carcinoma, pancreatic cancer, colorectal carcinoma (CRC), head and neck adenocarcinoma (salivary gland adenocarcinoma, lacrimal gland adenocarcinoma, adenocarcinoma of unknown primary of the neck), cervical cancer". No results are recorded here; the registry entry is the source.